Meningitis Vaccines Market Synopsis:
Meningitis Vaccines Market Size Was Valued at USD 3.58 Billion in 2023, and is Projected to Reach USD 8.86 Billion by 2032, Growing at a CAGR of 10.60 % From 2024-2032.
The Meningitis Vaccines market comprises vaccines, which are intended to prevent meningitis a severe, and occasionally, fulminant disease caused by bacterial invasion of the membranes covering the brain and spinal cord. They are intended to confer protection against the most important bacterial causes of meningitis, including Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type B. Meningitis vaccines are growing fast due to the continuously increasing incidences of meningitis cases all over the world, the shifting focus to preventive healthcare and the development of new vaccines and technologies.
Another major factor that has been instrumental in the meningitis vaccines market is a general consciousness about the bacterial meningitis in the entire world. National immunization programs which are provided diverse attention to high risk area have improved our vaccination rate and general health standards of our population. As a result, governments especially in the developing nations are putting in place intensified measures that compel the populace especially infants, children and the elderly to take the vaccination to a bid to fight meningitis.
The next factor is that technology still progresses with development of more safe and efficient meningitis vaccines, as well as increase their availability. Another factor for the growth of the market is the availability of combination vaccines which provide several strains of bacteria in a single shot. Also, equally, higher funding from the global health bodies like the WHO has prompted enhanced vaccination and increased need for meningitis vaccines across the different parts of the world.
Meningitis Vaccines Market Trend Analysis:
Production of next generation of vaccines
-
Another trend which defines the meningitis vaccines market is production of next generation of vaccines. These vaccines have the design to confer broader immunity for a wide range of bacterial strain to avoid the need for one specific vaccine for a given bacterial pathogen. It is for this reason that more priority has been accorded to doing further research in order to beef up on the formulations that are used in the preparation of vaccines so as to make them more effective and to lessen on the side effects that are normally associated with most vaccinations, this has boosted confidence in vaccination throughout the world.
- Furthermore, there has been a tendency to target broader populations in the developing zones where the incidence density of meningitis is given. Immunization activities are being supported globally by both international organizations and governments so as to create vaccine access within the low-income bearing nations. This trend is greatly important in reducing level of bacterial meningitis and enhance on overall health in those regions.
Growing need for meningitis vaccines
-
It is identified that there is a growing need for meningitis vaccines in the emerging markets thus presents a strong growth prospect. People in some countries in Asia Pacific, Africa and Latin America are getting vaccinated because there is increased emphasis on vaccinations to prevent spread of disease. With development of these regions’ health sectors, they open prospects for the introduction of meningitis vaccines, the prospects for both domestic and foreign producers.
- Furthermore, present and future advancements in the concept of combination vaccines are still open to improvement among market players regarding their products. Due to the possibility of vaccinating against several pathogens at once through the use of combination vaccines and owing to the reduced cost passed on to the consumer, combination vaccines such as the one which covers almost all parasitic diseases, including meningitis, will become widely used more in future. This will establish itself as the key competition threshold as offering vaccines that prevent several diseases will be a competitive advantage.
Meningitis Vaccines Market Segment Analysis:
Meningitis Vaccines Market is Segmented on the basis of Type, Product, End-User, and Region
By Type, Meningococcal Vaccines segment is expected to dominate the market during the forecast period
-
Meningitis vaccines market is divided across type as Meningococcal vaccines, Pneumococcal vaccines, Hib (Haemophilus influenzae type b) vaccines, and Other vaccines. Meningococcal vaccines are focused on Neisseria meningitidis and are common in immunization programmes because of impending potential outbreaks. Pneumococcal vaccines are vaccines that help combat S pneumonia which is a cause of meningitis and pneumonia in kids below five years and the elderly. Hib vaccines shield children against Haemophilus influenzae B-the bacterial infection that’s to blame for many different cases of meningitis and pneumonia in kids aged below five. The “Other Vaccines” category also groups vaccines that treat less frequent grounds for meningitis, though they prevent the disease as well.
By Product, Conjugate Vaccines segment expected to held the largest share
-
The meningitis vaccines market is also categorized by product into Conjugate Vaccines, Polysaccharide Vaccines and Combination vaccines. While using var like bacterial antigens with proteins to further the immune response, conjugate vaccines are popular for use in meningococcal and pneumococcal diseases. Conjugate vaccines are made of carbohydrates but from sugar molecules found on bacterial surfaces and provide immunity to particular pathogens; however, they are less effective in children under 5 years of age than conjugate vaccines. New technologies of vaccines being developed for several diseases in one preventor is becoming popular due to its efficiency and economic benefits.
Meningitis Vaccines Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast period
-
North America is the biggest market for meningitis vaccines because it is most developed from the perspective of both healthcare and awareness and has strong vaccination programs. For instance, the United States has adopted a complicated immunisation calendar in which children are supposed to be administered with vaccines for the types of meningitis and this has enhance high degree of compliance.
- Measures such as CDC immunization also encourage the use of vaccines acts as another support of vaccines. Moreover, it has encouragement from various healthcare policies towards meningitis prevention, and key players present in this region makes North America capture the largest share in the global market.
Active Key Players in the Meningitis Vaccines Market:
-
Bharat Biotech (India)
- Biovac Institute (South Africa)
- GlaxoSmithKline (United Kingdom)
- Johnson & Johnson (United States)
- MedImmune (United States)
- Merck & Co., Inc. (United States)
- Novartis AG (Switzerland)
- Pfizer Inc. (United States)
- Sanofi Pasteur (France)
- Serum Institute of India (India)
- Other Active Players
|
Global Meningitis Vaccines Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 3.58 Billion |
|
Forecast Period 2024-32 CAGR: |
10.60 % |
Market Size in 2032: |
USD 8.86 Billion |
|
Segments Covered: |
By Type |
|
|
|
By Product |
|
||
|
By End-User |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Meningitis Vaccines Market by Type
4.1 Meningitis Vaccines Market Snapshot and Growth Engine
4.2 Meningitis Vaccines Market Overview
4.3 Meningococcal Vaccines
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Meningococcal Vaccines: Geographic Segmentation Analysis
4.4 Pneumococcal Vaccines
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Pneumococcal Vaccines: Geographic Segmentation Analysis
4.5 Haemophilus Influenzae Type B (Hib) Vaccines
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Haemophilus Influenzae Type B (Hib) Vaccines: Geographic Segmentation Analysis
4.6 Other Vaccines
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 Other Vaccines: Geographic Segmentation Analysis
Chapter 5: Meningitis Vaccines Market by Product
5.1 Meningitis Vaccines Market Snapshot and Growth Engine
5.2 Meningitis Vaccines Market Overview
5.3 Conjugate Vaccines
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Conjugate Vaccines: Geographic Segmentation Analysis
5.4 Polysaccharide Vaccines
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Polysaccharide Vaccines: Geographic Segmentation Analysis
5.5 Combination Vaccines
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Combination Vaccines: Geographic Segmentation Analysis
Chapter 6: Meningitis Vaccines Market by End-User
6.1 Meningitis Vaccines Market Snapshot and Growth Engine
6.2 Meningitis Vaccines Market Overview
6.3 Hospitals
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Hospitals: Geographic Segmentation Analysis
6.4 Clinics
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Clinics: Geographic Segmentation Analysis
6.5 Research Institutes
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Research Institutes: Geographic Segmentation Analysis
6.6 Others
6.6.1 Introduction and Market Overview
6.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.6.3 Key Market Trends, Growth Factors and Opportunities
6.6.4 Others: Geographic Segmentation Analysis
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Benchmarking
7.1.2 Meningitis Vaccines Market Share by Manufacturer (2023)
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Mergers and Acquisitions
7.2 GLAXOSMITHKLINE (UNITED KINGDOM)
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Role of the Company in the Market
7.2.5 Sustainability and Social Responsibility
7.2.6 Operating Business Segments
7.2.7 Product Portfolio
7.2.8 Business Performance
7.2.9 Key Strategic Moves and Recent Developments
7.2.10 SWOT Analysis
7.3 MERCK & CO. INC. (UNITED STATES)
7.4 PFIZER INC. (UNITED STATES)
7.5 SANOFI PASTEUR (FRANCE)
7.6 SERUM INSTITUTE OF INDIA (INDIA)
7.7 NOVARTIS AG (SWITZERLAND)
7.8 BHARAT BIOTECH (INDIA)
7.9 JOHNSON & JOHNSON (UNITED STATES)
7.10 BIOVAC INSTITUTE (SOUTH AFRICA)
7.11 MEDIMMUNE (UNITED STATES)
7.12 OTHER ACTIVE PLAYERS
Chapter 8: Global Meningitis Vaccines Market By Region
8.1 Overview
8.2. North America Meningitis Vaccines Market
8.2.1 Key Market Trends, Growth Factors and Opportunities
8.2.2 Top Key Companies
8.2.3 Historic and Forecasted Market Size by Segments
8.2.4 Historic and Forecasted Market Size By Type
8.2.4.1 Meningococcal Vaccines
8.2.4.2 Pneumococcal Vaccines
8.2.4.3 Haemophilus Influenzae Type B (Hib) Vaccines
8.2.4.4 Other Vaccines
8.2.5 Historic and Forecasted Market Size By Product
8.2.5.1 Conjugate Vaccines
8.2.5.2 Polysaccharide Vaccines
8.2.5.3 Combination Vaccines
8.2.6 Historic and Forecasted Market Size By End-User
8.2.6.1 Hospitals
8.2.6.2 Clinics
8.2.6.3 Research Institutes
8.2.6.4 Others
8.2.7 Historic and Forecast Market Size by Country
8.2.7.1 US
8.2.7.2 Canada
8.2.7.3 Mexico
8.3. Eastern Europe Meningitis Vaccines Market
8.3.1 Key Market Trends, Growth Factors and Opportunities
8.3.2 Top Key Companies
8.3.3 Historic and Forecasted Market Size by Segments
8.3.4 Historic and Forecasted Market Size By Type
8.3.4.1 Meningococcal Vaccines
8.3.4.2 Pneumococcal Vaccines
8.3.4.3 Haemophilus Influenzae Type B (Hib) Vaccines
8.3.4.4 Other Vaccines
8.3.5 Historic and Forecasted Market Size By Product
8.3.5.1 Conjugate Vaccines
8.3.5.2 Polysaccharide Vaccines
8.3.5.3 Combination Vaccines
8.3.6 Historic and Forecasted Market Size By End-User
8.3.6.1 Hospitals
8.3.6.2 Clinics
8.3.6.3 Research Institutes
8.3.6.4 Others
8.3.7 Historic and Forecast Market Size by Country
8.3.7.1 Russia
8.3.7.2 Bulgaria
8.3.7.3 The Czech Republic
8.3.7.4 Hungary
8.3.7.5 Poland
8.3.7.6 Romania
8.3.7.7 Rest of Eastern Europe
8.4. Western Europe Meningitis Vaccines Market
8.4.1 Key Market Trends, Growth Factors and Opportunities
8.4.2 Top Key Companies
8.4.3 Historic and Forecasted Market Size by Segments
8.4.4 Historic and Forecasted Market Size By Type
8.4.4.1 Meningococcal Vaccines
8.4.4.2 Pneumococcal Vaccines
8.4.4.3 Haemophilus Influenzae Type B (Hib) Vaccines
8.4.4.4 Other Vaccines
8.4.5 Historic and Forecasted Market Size By Product
8.4.5.1 Conjugate Vaccines
8.4.5.2 Polysaccharide Vaccines
8.4.5.3 Combination Vaccines
8.4.6 Historic and Forecasted Market Size By End-User
8.4.6.1 Hospitals
8.4.6.2 Clinics
8.4.6.3 Research Institutes
8.4.6.4 Others
8.4.7 Historic and Forecast Market Size by Country
8.4.7.1 Germany
8.4.7.2 UK
8.4.7.3 France
8.4.7.4 The Netherlands
8.4.7.5 Italy
8.4.7.6 Spain
8.4.7.7 Rest of Western Europe
8.5. Asia Pacific Meningitis Vaccines Market
8.5.1 Key Market Trends, Growth Factors and Opportunities
8.5.2 Top Key Companies
8.5.3 Historic and Forecasted Market Size by Segments
8.5.4 Historic and Forecasted Market Size By Type
8.5.4.1 Meningococcal Vaccines
8.5.4.2 Pneumococcal Vaccines
8.5.4.3 Haemophilus Influenzae Type B (Hib) Vaccines
8.5.4.4 Other Vaccines
8.5.5 Historic and Forecasted Market Size By Product
8.5.5.1 Conjugate Vaccines
8.5.5.2 Polysaccharide Vaccines
8.5.5.3 Combination Vaccines
8.5.6 Historic and Forecasted Market Size By End-User
8.5.6.1 Hospitals
8.5.6.2 Clinics
8.5.6.3 Research Institutes
8.5.6.4 Others
8.5.7 Historic and Forecast Market Size by Country
8.5.7.1 China
8.5.7.2 India
8.5.7.3 Japan
8.5.7.4 South Korea
8.5.7.5 Malaysia
8.5.7.6 Thailand
8.5.7.7 Vietnam
8.5.7.8 The Philippines
8.5.7.9 Australia
8.5.7.10 New Zealand
8.5.7.11 Rest of APAC
8.6. Middle East & Africa Meningitis Vaccines Market
8.6.1 Key Market Trends, Growth Factors and Opportunities
8.6.2 Top Key Companies
8.6.3 Historic and Forecasted Market Size by Segments
8.6.4 Historic and Forecasted Market Size By Type
8.6.4.1 Meningococcal Vaccines
8.6.4.2 Pneumococcal Vaccines
8.6.4.3 Haemophilus Influenzae Type B (Hib) Vaccines
8.6.4.4 Other Vaccines
8.6.5 Historic and Forecasted Market Size By Product
8.6.5.1 Conjugate Vaccines
8.6.5.2 Polysaccharide Vaccines
8.6.5.3 Combination Vaccines
8.6.6 Historic and Forecasted Market Size By End-User
8.6.6.1 Hospitals
8.6.6.2 Clinics
8.6.6.3 Research Institutes
8.6.6.4 Others
8.6.7 Historic and Forecast Market Size by Country
8.6.7.1 Turkiye
8.6.7.2 Bahrain
8.6.7.3 Kuwait
8.6.7.4 Saudi Arabia
8.6.7.5 Qatar
8.6.7.6 UAE
8.6.7.7 Israel
8.6.7.8 South Africa
8.7. South America Meningitis Vaccines Market
8.7.1 Key Market Trends, Growth Factors and Opportunities
8.7.2 Top Key Companies
8.7.3 Historic and Forecasted Market Size by Segments
8.7.4 Historic and Forecasted Market Size By Type
8.7.4.1 Meningococcal Vaccines
8.7.4.2 Pneumococcal Vaccines
8.7.4.3 Haemophilus Influenzae Type B (Hib) Vaccines
8.7.4.4 Other Vaccines
8.7.5 Historic and Forecasted Market Size By Product
8.7.5.1 Conjugate Vaccines
8.7.5.2 Polysaccharide Vaccines
8.7.5.3 Combination Vaccines
8.7.6 Historic and Forecasted Market Size By End-User
8.7.6.1 Hospitals
8.7.6.2 Clinics
8.7.6.3 Research Institutes
8.7.6.4 Others
8.7.7 Historic and Forecast Market Size by Country
8.7.7.1 Brazil
8.7.7.2 Argentina
8.7.7.3 Rest of SA
Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies
Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research
|
Global Meningitis Vaccines Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 3.58 Billion |
|
Forecast Period 2024-32 CAGR: |
10.60 % |
Market Size in 2032: |
USD 8.86 Billion |
|
Segments Covered: |
By Type |
|
|
|
By Product |
|
||
|
By End-User |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
